NEVVI Medicare utilization intelligence
Compare this code with others

Jump to the result views

Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg HCPCS · Treatment
Classification Treatment › Injections and Infusions (nononcologic) › Injection - Colony Stimulating Factors (CMS RBCS)
First observed 2018
National scale 193,323 services · est. ▲ 97.1% YoY · 3,699 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 97,926 observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window · National figures — the PA market is below

See it in full: sestamibi, the nuclear heart-imaging tracer (A9500), in Arizona is open as a live example — every paid panel, on real data.

View the live example →
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary
Market Brief Q5108
A shareable PDF report summarizing this market’s size, trends, and providers.
Preview this Brief →

This market's Overview — its estimated all-Medicare volume, national benchmarks, and what the field charges and is paid — is part of Explore.

See what Medicare pays

An Explore subscription, $249 a seat a year, opens the Overview on every code, group and clinician page, including what the market charges and is paid.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

View the live example →

Included in Explore. Part of a Deep Dive.
Continue from here

Browse Medicare billing by specialty →